Japan Peanut Allergy Treatment Market Size, Share, and COVID-19 Impact Analysis, By Drug Class (Antihistamines, Epinephrine, Immunotherapies, and Others), By Route of Administration (Oral, Injectable, and Others), and Japan Peanut Allergy Treatment Market Insights, Industry Trend, Forecasts to 2035

Japan Peanut Allergy Treatment Market Insights Forecasts to 2035

• The Japan Peanut Allergy Treatment Market Size Was Estimated at USD 18.1 Million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 11.89% from 2025 to 2035
• The Japan Peanut Allergy Treatment Market Size is Expected to Reach USD 62.3 Million by 2035

According to a research report published by Spherical Insights & Consulting, the Japan peanut allergy treatment market is anticipated to reach USD 62.3 million by 2035, growing at a CAGR of 11.89% from 2025 to 2035. The Japan peanut allergy treatment market is driven by various factors, including increasing peanut allergy prevalence, advancements in innovative therapeutics, growing awareness of anaphylaxis risks, increased adoption of immunotherapies, and advancements in diagnostics technologies.

Market Overview

Peanut allergy treatment refers to the management and therapeutic techniques used to reduce or prevent allergic responses caused by peanut consumption or exposure. The Japan peanut allergy treatment market focuses on diagnosis, management, and treatment of peanut allergies. These treatments include emergency drugs like epinephrine and antihistamines, as well as long-term options like immunotherapies, which try to desensitize patients to peanuts and lower the severity of allergic responses. Peanut allergy treatment demand is mainly driven by enhanced diagnostic capabilities that allow for earlier detection, increased patient and caregiver education, and a strong pipeline of innovative immunotherapies focused on desensitization or prevention. The people are becoming more aware of food allergies and innovative therapies, which further expand the market for peanut allergy treatment. The growing popularity of personalized products is are key trend in this market. This trend presents an opportunity for the development of personalized medicines based on patient profiles.

Report Coverage

This research report categorizes the market for the Japan peanut allergy treatment market based on various segments and regions, and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan peanut allergy treatment market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan peanut allergy treatment market.

Driving Factors

The rising prevalence of peanut allergy is the primary driving force for this market. Rising awareness of food allergies among healthcare professionals and the general public has led to a greater demand for effective treatment alternatives. The consumers' growing preference for long-term treatments like oral and epicutaneous immunotherapy further fuels the market expansion. Additionally, a rise in innovative treatments plays an important role in market expansion.

Restraining Factors

The development and bringing new treatments require a high cost, which makes the final product expensive, further limiting the market expansion. Several immunotherapies have a risk of adverse reactions, hence some healthcare providers and patients hesitate to adopt such treatments.

Market Segmentation

The Japan peanut allergy treatment market share is classified into drug class and route of administration.

• The epinephrine segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period.   

The Japan peanut allergy treatment market is segmented by drug class into antihistamines, epinephrine, immunotherapies, and others. Among these, the epinephrine segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is because they used them as primary emergency solutions, with long-term effectiveness. It aids in reversing life-threatening symptoms like swelling of the airway and low blood pressure.

• The injectable segment held the highest share in 2024 and is expected to grow at a substantial CAGR during the forecast period.     

The Japan peanut allergy treatment market is segmented by route of administration into oral, injectable, and others. Among these, the injectable segment held the highest share in 2024 and is expected to grow at a substantial CAGR during the forecast period. This segmental growth is attributed to its rapid effectiveness in emergency solutions. Additionally, they give a rapid effect as compared to other routes.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan peanut allergy treatment market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes Application development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Astellas Pharma Inc.
• Sanofi
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
• Shionogi & Co., Ltd.
• Mitsubishi Tanabe Pharma Corporation
• Kowa Pharmaceutical Co., Ltd. 
• Others

Recent Developments

• In August 2023, Takeda Pharmaceutical launched an oral immunotherapy for peanut allergies in Japan, highlighting the growing focus on innovative allergy treatments.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan peanut allergy treatment market based on the below-mentioned segments:

Japan Peanut Allergy Treatment Market, By Drug Class

• Antihistamines
• Epinephrine
• Immunotherapies
• Others

Japan Peanut Allergy Treatment Market, By Route of Administration

• Oral
• Injectable
• Others